INKT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
200.0K
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
200.0K
0
0
0
0
Operating Expenses
2.8M
-11.8%
3.2M
+11.6%
2.9M
+6.5%
2.7M
-15.0%
3.2M
R&D
1.8M
-4.4%
1.9M
+56.7%
1.2M
-20.4%
1.5M
+32.4%
1.1M
SG&A
1.0M
-22.3%
1.3M
-20.7%
1.7M
-4.9%
1.8M
-4.5%
1.8M
Operating Income
-2637263
+18.0%
-3216894
-11.6%
-2881787
-6.5%
-2705459
+15.0%
-3183594
EBITDA
-2601198
+18.2%
-3180830
-11.8%
-2845721
-6.7%
-2666896
+15.1%
-3139940
Net Income
-2552283
+18.4%
-3128201
-14.1%
-2742368
-5.4%
-2602103
+9.9%
-2887709
EPS (Basic)
$-0.50
+19.4%
$-0.62
-8.8%
$-0.57
-3.6%
$-0.55
+15.4%
$-0.65
EPS (Diluted)
$-0.50
+19.4%
$-0.62
-8.8%
$-0.57
-3.6%
$-0.55
+15.4%
$-0.65
Shares (Diluted)
5.1M
+1.6%
5.0M
+4.7%
4.8M
+2.3%
4.7M
+5.6%
4.4M
MiNK Therapeutics (INKT) — Financials